Dr. Sontheimer is a researcher and educator with a life-long interest in Neuroscience. A native of Germany, he obtained a Masters degree in evolutionary comparative Neuroscience, where he worked on the development of occulomotor reflexes. In 1989, he obtained a doctorate in Biophysics and Cellular & Molecular Neuroscience form the University of Heidelberg studying biophysical changes that accompany the development of oligodendrocytes, the principle myelinating cells of the nervous system. He moved to the United States, where he later became a citizen, for post-doctoral studies at Yale University. His independent research career began at Yale in 1991 and continued at the University of Alabama Birmingham from 1994-2015, and, more recently at Virginia Tech and the University of Virginia. His research focuses on the role of glial support cells in health and disease. His laboratory has made major discoveries that led to two clinical trials using novel compounds to treat malignant gliomas. His research led to over 190 peer-reviewed publications. For the clinical development of his discoveries, Dr. Sontheimer started a biotechnologies company, Transmolecular Inc., which conducted both phase I and II clinical trials with the anti-cancer agent chlorotoxin. Morphotec Pharmaceuticals, who will be conducting the phase III clinical trials, recently acquired this technology. As educator, Dr. Sontheimer has been active in teaching Medical Neuroscience, graduate Cellular and Molecular Neuroscience, and, for the past 10 years, he has offered both graduate and undergraduate courses on Diseases of the Nervous System. In 2005, Dr. Sontheimer became director of the Civitan International Research Center, a philanthropically supported center in Birmingham AL devoted to the study and treatment of children with developmental disabilities, ranging from Down's syndrome to Autism. In this capacity, Dr. Sontheimer was frequently tasked explaining complex scientific processes to a lay audience. Recognizing the need to further educate the public about neurological disorders using language that is accessible to an educated public motivated Dr. Sontheimer to write a textbook on Diseases of the Nervous system. To assure that the material is comprehensive yet readily understandable, he wrote large parts of this text while on sabbatical leave at Rhodes College in Memphis, where he taught undergraduates while testing his book on this group of talented third and fourth year Neuroscience students. In 2015 Dr. Sontheimer was tapped to found a School of Neuroscience at Virginia Tech with the goal to offer a unique Neuroscience education to an increasing number of undergraduates. As the first of its kind, this enterprise devoted an entire School to a variety of Neuroscience experiences that include majors in clinical, experimental, cognitive, systems, computational and social Neuroscience. In 2020 Dr. Sontheimer was recruited to the University of Virginia, School of Medicine as Chair of Neuroscience with the mission to build this Department into a leading research enterprise devoted to discovery and translation science in Neuroimmunology and Neurodegenerative diseases. Dr. Sontheimer continues to manage a very active research laboratory where he involves a spectrum of trainees ranging from undergraduates to post-doctoral scientists. Dr. Sontheimer has trained over 50 Ph.D. and MD/Ph.D students and post-doctoral fellows, many of whom have independent faculty positions today.
The study of the brain continues to expand at a rapid pace providing fascinating insights into the basic mechanisms underlying nervous system illnesses. New tools, ranging from genome sequencing to non-invasive imaging, and research fueled by public and private investment in biomedical research has been transformative in our understanding of nervous system diseases and has led to an explosion of published primary research articles. Diseases of the Nervous System, Second Edition, summarizes the current state of basic and clinical knowledge for the most common neurological and neuropsychiatric conditions. In a systematic progression, each chapter covers either a single disease or a group of related disorders ranging from static insults to primary and secondary progressive neurodegenerative diseases, neurodevelopmental illnesses, illnesses resulting from nervous system infection and neuropsychiatric conditions. Chapters follow a common format and are stand-alone units, each covering disease history, clinical presentation, disease mechanisms and treatment protocols. Dr. Sontheimer also includes two chapters which discuss common concepts shared among the disorders and how new findings are being translated from the bench to the bedside. In a final chapter, he explains the most commonly used neuroscience jargon. The chapters address controversial issues in current day neuroscience research including translational research, drug discovery, ethical issues, and the promises of personalized medicine. This new edition features new chapters on Pain and Addiction to highlight the growing opioid crisis and the ethical issue of prescriptions drug abuse. This book provides an introduction for course adoption and an introductory tutorial for students, scholars, researchers and medical professionals interested in learning the state of the art concerning our understanding and treatment of diseases of the nervous system. Each chapter includes suggested further readings and/or journal club recommendations. - 2016 PROSE Award winner of the Best Textbook Award in Biological and Life Sciences- Provides a focused tutorial introduction to the core diseases of the nervous system- Includes comprehensive introductions to Stroke, Epilepsy, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Head and Spinal Cord Trauma, Multiple Sclerosis, Brain Tumors, Depression, Schizophrenia and many other diseases of the nervous system- Covers more than 40 diseases from the foundational science to the best treatment protocols- Includes discussions of translational research, drug discovery, personalized medicine, ethics, and neuroscience- New Edition features two new chapters on Pain and Addiction
Erscheint lt. Verlag | 20.5.2021 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Allgemeines / Lexika |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie | |
Studium ► 2. Studienabschnitt (Klinik) ► Pathologie | |
Naturwissenschaften ► Biologie ► Humanbiologie | |
Naturwissenschaften ► Biologie ► Zoologie | |
Technik | |
ISBN-10 | 0-12-821396-5 / 0128213965 |
ISBN-13 | 978-0-12-821396-4 / 9780128213964 |
Haben Sie eine Frage zum Produkt? |
Größe: 218,8 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich